Fargo, NORTH%20DAKOTA5 Active Studies

Atopic Dermatitis Clinical Trials in Fargo, NORTH%20DAKOTA

Find 5 actively recruiting atopic dermatitis clinical trials in Fargo, NORTH%20DAKOTA. Connect with local research sites and explore new treatment options.

5
Active Trials
5
Sponsors
720
Enrolling

Recruiting Atopic Dermatitis Studies in Fargo

RecruitingFargo, NORTH%20DAKOTANCT06881251

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis....

240 participants
Janssen Research & Development, LLC
View Study Details
RecruitingFargo, NORTH%20DAKOTANCT07037901

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo....

220 participants
Inmagene LLC
View Study Details
RecruitingFargo, NORTH%20DAKOTANCT06790121

A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

This is a parallel, Phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of lunsekimig monotherapy in adult participants (aged 18 ...

144 participants
Sanofi
View Study Details
RecruitingFargo, NORTH%20DAKOTANCT04966481

Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

This multicenter, open-label, randomized phase 3 trial will determine if palbociclib and cetuximab (Arm 1) improves overall survival (OS) in comparison to cetuximab monotherapy (Arm 2) in patients wit...

81 participants
Washington University School of Medicine
View Study Details
RecruitingFargo, NORTH%20DAKOTANCT06768671

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS....

35 participants
MoonLake Immunotherapeutics AG
View Study Details

About Atopic Dermatitis Clinical Trials in Fargo

Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.

There are currently 5 atopic dermatitis clinical trials recruiting participants in Fargo, NORTH%20DAKOTA. These studies are seeking a combined 720 participants. Research is being sponsored by Janssen Research & Development, LLC, Inmagene LLC, Sanofi and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atopic Dermatitis Clinical Trials in Fargo — FAQ

Are there atopic dermatitis clinical trials in Fargo?

Yes, there are 5 atopic dermatitis clinical trials currently recruiting in Fargo, NORTH%20DAKOTA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Fargo?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Fargo research site will contact you about next steps.

Are clinical trials in Fargo free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Fargo studies also compensate for your time and travel.

What atopic dermatitis treatments are being tested?

The 5 active trials in Fargo are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.

Data updated March 2, 2026 from ClinicalTrials.gov